European antitrust regulators have given their blessing to the $41 billion merger of healthcare giants Merck and Schering-Plough. "Approval from the European Commission marks a key milestone for the completion of our transaction with Schering-Plough" said Richard Clark, Merck’s chairman and chief executive officer in a statement Friday.
Full Article at Dealbook